THE LUMBROKINASE DBLS 1033 EFFECT
IN
PERIPHERAL ARTERY DISEASE
Suzanna Ndraha*,
Fendra Wician*, Henny Tannady*, Helena Yap*, Marshell Tendean*
*. Department of
Internal Medicine UKRIDA Christian University, Jakarta-indonesia
ABSTRACT
Introduction. Lumbrokinase act
as oral anti-thrombotic and thrombolytic is promising to treat cerebrovascular
disease, including Peripheral Artery Disease (PAD). The hallmarks of Peripheral Artery Disease
(PAD) are intermittent claudication, rest calf pain and gangrenous ulcer.
Objective. This study aims
to describe the clinical picture and risk factors of intermittent claudication
in Koja Hospital, and to ascertain the efficacy of lumbrokinase DBLS1033 in
patients with intermittent claudication.
Methods. The study was done
among 20 patients in Koja hospital Internal Medicine outpatient department (IM-OPD)
from April 2013 to August 2013. This is a preliminary RCT study. Patients were
interviewed and measured for Ankle Brachial Index (ABI), they were divided into
two groups. Group A was given lumbrokinase DBLS1033 (DisolfÒ) tablet, 1 tab 3 times daily for 2 weeks and group B was
given placebo. After 2 weeks, ABI were re-measured. Statistical analysis were
done using SPSS 20.
Results. Among 20 subjects with ABI £ 0.9, 90% were woman, mean age 54.4±7.2 yrs. Independent risk factors
related with PAD were: hypertension, diabetes, dyslipidemia and lack of
exercise. Before treatment, ABI in DBLS1033 group was 0.81±0.05 and 0.82± 0.04
in control group (p=0.73). After treatment, ABI in DBLS1033 group was 1.08±0.7
and 0.78±0.03 in control group (p=0.00). There was significantly difference in improvement
of ABI between DBLS1033 group and control group (0.27 vs -0.04, p=0.00). Within DBLS1033 group, mean ABI pre-test 0.81±0.05 and post-test
1.08±0.17 (p=0.00),
ABI improvement 0.27±1.6. Within control group, the mean ABI pre-test 0.82± 0.04 and
post-test 0.78±0.03(p=0.02),
with ABI reduction 0.04±0.02
Conclusion. PAD patients
in Koja Hospital were 90%
woman, mean age 54.4 years old. Independent risk factors
for PAD were hypertension,
diabetes, dyslipidemia and lack of exercise. Lumbrokinase DBLS1033 showed to
improve ABI in patients with intermittent claudication.
Artikel Lengkap Penelitian ini dipublikasi di Jurnal
MEDICINUS
Scientific Journal of Pharmaceutical Development and Medical Application
vol 27 no 1 April 2014
ISSN 1979-39x
http://cme.medicinus.co/mod/resource/view.php?id=17
 |
| Penelitian DLBS |
No comments:
Post a Comment